Phase 3 N=253 Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
Allergic Conjunctivitis
Primary: Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 — -2.57; -2.62 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
Asthma
Primary: Asthma Control Test — 17.5; 13; 12; 10 units on a scale
N/A N=30 A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects
Erythema · Edema
Primary: Number of Participants With Observed Local Erythema — 0 participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
N/A N=15 Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions — 6.3; 17.5; 11.4; 5.6 minutes — p=<0.05
Phase 3 N=978 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Glioblastoma · Gliosarcoma · Supratentorial Glioblastoma
Primary: Overall Survival (OS) — 16.1; 15.7 months — p=0.11
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
Phase 3 N=484 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
Diabetes Mellitus Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.34; -0.90 percentage of hemoglobin — p=<0.0001
Phase 3 N=446 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.40; -0.71 percentage of hemoglobin — p=<0.0001
N/A N=52 Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy
Ileostomy · Colostomy
Primary: Fit to the Peristomal Area, Measured by a 5-point Scale Ranging From "Very Poor" to "Very Good". — 56.9; 10.6; 29.4; 27.7 percentage of subjects answering
Phase 3 N=319 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
Type 2 Diabetes Mellitus
Primary: Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24 — 12.0; 7.5 percentage of…
Phase 1 N=23 A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Alectinib: Cohort A — 27.6; 35.0 nanograms per milliliter (ng/mL)
Phase 1 N=16 Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
End Stage Renal Disease
Primary: Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban — 125.6; 98.9; 113.6 ng/mL
N/A N=35 Safety and Performance Study of the Shockwave Lithoplasty System
Peripheral Arterial Disease
Primary: Composite of New-onset Major Adverse Events (MAE) — 0 participants
Phase 3 N=312 Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP) — 10; 15 participants — p=0.2434